Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons.
First drug to modestly slow Alzheimer’s cognitive decline, based on 1,800 patients.
The FDA Advisory Committee’s endorsement of Leqembi paves way for traditional approval, ushers in a new era for Alzheimer’s
The FDA has approved the supplemental New Drug Application (sNDA) of REXULTI® (brexpiprazole) for the treatment of agitation associated with Alzheimer’s. It’s the first such treatment to be approved in the US. Learn more.
Eli Lilly Company’s TRAILBLAZER-ALZ 2 Phase 3 study shows that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Learn more.
The new Alzheimer’s injections Aduhelm and Lecanemab offer hope. Now, Mastinimab is trying to break through to the next level with a simpler pill. Mastinimab fights Alzheimer’s via a revolutionary mechanism of action. Learn why the FDA approved Mastinimab’s final round of trials.
VIDEO + ARTICLE: Phase II/III trials are begining in the Tau NextGen study. The study will assess the effect of Lecanemab, an experimental anti-amyloid therapy,
OLD-NEW DRUG RESEARCH: The diuretic bumetanide, used for more than 30 years to treat hypertension and heart failure, was also found to reverse signs of
VIDEO + ARTICLE: An experimental drug produced by Annovis has received its generic name following successful completion of its Phase II trials. Buntanetap is intended
U.S. dementia rates dropped 65% in 40 years. Even so, this predicts a 25% rise in total cases by 2050, due to population aging. See the real numbers. Learn why predictions of dementia doubling by 2050 are sensationalized fake news.
Perseverance and spirit have done wonders in all ages. (George Washington)
DIET: Years of good research suggests caffeine lowers dementia risk. New research uncovers a subtle twist – AFTER dementia kicks in, caffeine may exert negative effects. Get the facts.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
